{"id":482048,"date":"2020-05-01T11:18:01","date_gmt":"2020-05-01T11:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=482048"},"modified":"2020-05-01T11:18:01","modified_gmt":"2020-05-01T11:18:01","slug":"vasomotor-symptoms-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vasomotor-symptoms-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies_482048.html","title":{"rendered":"Vasomotor Symptoms Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies"},"content":{"rendered":"
\"Vasomotor<\/a><\/p>\n
\n
DelveInsight <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cVasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Vasomotor Symptoms , historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on <\/strong>Vasomotor Symptoms Market Insights, Epidemiology and Market Forecast-2030  <\/strong><\/p>\n

DelveInsight’s “Vasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2030<\/a>” report delivers an in-depth understanding of the Vasomotor Symptoms , historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

 <\/p>\n

The Vasomotor Symptoms market report provides current treatment practices, emerging drugs, Vasomotor Symptoms market share of the individual therapies, current and forecasted Vasomotor Symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Vasomotor Symptoms treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

 <\/p>\n

Key benefits of the report
<\/strong>1. Vasomotor Symptoms market report covers a descriptive overview and comprehensive insight of the Vasomotor Symptoms epidemiology and Vasomotor Symptoms market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Vasomotor Symptoms market report provides insights on the current and emerging therapies.
3. Vasomotor Symptoms market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Vasomotor Symptoms market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Vasomotor Symptoms market.<\/p>\n

“Vasomotor Symptoms Market Size is increasing at a CAGR of 7%”<\/p>\n

Request for sample pages here -><\/strong> https:\/\/www.delveinsight.com\/sample-request\/vasomotor-symptoms-market<\/a><\/p>\n

\"\"<\/p>\n

Vasomotor Symptoms (VMS) are one of the major symptoms of menopause that principally includes hot flashes (HF) and night sweats (NS) during menopause and occurs in majority of women across the globe. A woman with VMS, experiences abundant heat accompanied by sweating and flushing, especially around head, neck, chest, and upper back region. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones.<\/strong><\/p>\n

Menopause is characterized by physiologic and psychosocial changes in a woman’s life. VMS, and the sleep and mood disturbances that often result from these, can have a significant negative impact on overall quality of life (QOL) for a substantial number of women. <\/strong><\/p>\n

Hot flashes are often described as episodic sensations of heat, intense sweating, and flushing affecting the face and chest, which are often accompanied by palpitations and anxiety. Each particular episode lasts 3–10 minutes and episodes can recur with varying frequency. Some women experience hot flashes hourly or daily, whereas for others they may occur occasionally. The age at onset of hot flashes also varies from woman to woman. <\/strong><\/p>\n

Night sweats are Hot Flashes that occur with heavy perspiration during sleep and cause sleep disruption. Women experiencing night sweats have greater motor restlessness in bed, less efficient sleep and a reduced feeling of restlessness in the morning compared to women without these symptoms.<\/strong><\/p>\n

Drugs covered
1. Donesta
2. NT-814
3. FP-101
4. Fezolinetant
5. SJX 653
6. MT-8554
And many others<\/p>\n

The key players in Vasomotor Symptoms market are:
1. Mithra Pharmaceuticals (Donesta Biosciences)
2. KaNDy Therapeutics
3. Fervent Pharmaceuticals
4. Astellas Pharma
5. Sojournix
6. Mitsubishi Tanabe Pharma
And many others<\/p>\n

Table of contents
1. Key Insights
2. Vasomotor Symptoms Market Overview at a Glance
3. Executive summary
4. Organizations
5. Vasomotor Symptoms Epidemiology and Market Methodology
6. Vasomotor Symptoms associated with menopause Disease Background and Overview
7. Vasomotor Symptoms Epidemiology and Patient Population
8. Total Vasomotor Symptoms in Post-menopause Prevalent cases in 7MM
9. Country Wise Hot Flashes Associated with Post-menopause Epidemiology
9.1. United States
9.2. EU5 Countries
9.3. Germany
9.4. France
9.5. Italy
9.6. Spain
9.7. United Kingdom
9.8. Japan
10. Vasomotor Symptoms Treatment Algorithm, Current Treatment, and Medical Practices
11. Unmet Needs
12. Vasomotor Symptoms Marketed drugs by class
12.1. Hormonal Therapies
12.2. Non-hormonal Therapies
12.3. Recent additions in Hormonal therapies
12.4. Bijuva: TherapeuticsMD
13. Vasomotor Symptoms Emerging Therapies
13.1. Key Cross Competition
13.2. Hormonal Based therapies
13.3. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)
13.4. Non-Hormonal Based therapies
13.5. NT-814: KaNDy Therapeutics
13.6. FP-101: Fervent Pharmaceuticals
13.7. Fezolinetant: Astellas Pharma
13.8. Other Potential therapies
13.9. SJX 653: Sojournix
13.10. MT-8554: Mitsubishi Tanabe Pharma
14. Hot Flashes 7 Major Market Analysis
15. Seven Major Market Outlook
15.1. United States Market Size
15.2. Germany
15.3. France
15.4. Italy
15.5. Spain
15.6. United Kingdom
15.7. Japan
16. Market Drivers
17. Market Barriers
18. SWOT
19. Case Studies
20. KOL Views
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight<\/p>\n

Request for sample pages here -> https:\/\/www.delveinsight.com\/sample-request\/vasomotor-symptoms-market<\/a><\/p>\n

Related Reports:<\/strong><\/p>\n

Vasomotor symptoms (Hot flashes\/Night sweats)– Epidemiology Forecast—2030<\/a><\/p>\n

DelveInsight’s Vasomotor symptoms Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of the 7MM.<\/p>\n

Vasomotor Symptoms of Menopause – Pipeline Insights, 2020<\/a><\/p>\n

Vasomotor Symptoms of Menopause Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vasomotor Symptoms of Menopause market.<\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight\u2019s \u201cVasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Vasomotor Symptoms , historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU5 (Germany, Spain, Italy, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-482048","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=482048"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482048\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=482048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=482048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=482048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}